Vertex Pharmaceuticals Incorporated (VRTX) Stock Analysis & AI Equity Report
Vertex Pharmaceuticals Incorporated (VRTX) overview
Vertex Pharmaceuticals Incorporated (VRTX) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 12,001m and operating profit of USD 4,173m; the year-end share price was 453.36 USD and market capitalisation was USD 115,149m. Vertex Pharmaceuticals Incorporated is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Vertex Pharmaceuticals Incorporated's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers, develops and commercializes medicines for serious diseases, with an emphasis on specialty markets. It has approved medicines for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain. The company also develops clinical-stage and earlier research programs in areas including kidney disease, neuropathic pain, type 1 diabetes and myotonic dystrophy.
Generate the Vertex Pharmaceuticals Incorporated report
Vertex Pharmaceuticals Incorporated is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Vertex Pharmaceuticals Incorporated and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Vertex Pharmaceuticals Incorporated
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.